Results 171 to 180 of about 1,574,312 (309)

Monitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer

Molecular Oncology, EarlyView.
Monitoring circulating tumor DNA (ctDNA) in patients with operable breast cancer can reveal disease relapse earlier than radiology in a subset of patients. The failure to detect ctDNA in some patients with recurrent disease suggests that ctDNA could serve as a supplement to other monitoring approaches.
Kristin Løge Aanestad, Marie Austdal, Oddmund Nordgård, Gunnar Mellgren, Satu Oltedal, Marie L. Austbø, Ylva H. Vignes, Thomas Helland, Kristin Jonsdottir, Tone H. Lende, Emilius A. M. Janssen, Bjørnar Gilje, Kjersti Tjensvoll, PBCB study group, Gunnar Mellgren, Tone Hoel Lende, Anette Heie, Kristin Viste, Anita Røyneberg Alvheim, Emiel AM Janssen, Kristin Jonsdottir, Ann Cathrine Kroksveen, Thomas Helland, Einar Gudlaugsson, Oddmund Nordgård, Satu Oltedal, Kristin Løge Aanestad, Jan Terje Kvaløy, Kirsten Lode, Kari Britt Hagen, Marie Austdal, Ylva H. Vignes, Siri Tungland Sola, Nina Egeland Amundsen, Finn Magnus Eliassen, Emeritus Ernst A Lien   +35 more
wiley   +1 more source

Prognostic score predicts overall survival following complete urinary tract extirpation

, 2020
Murat Akand, Tim Muilwijk, Frank Van der Aa, Thomas Gevaert, Uroš Milenković, Lisa Moris, Wim Blyweert, Hendrik Van Poppel, Maarten Albersen, Steven Joniau   +9 more
openalex   +1 more source

Three Year Local Control, Overall Survival, and Toxicity From a Prospective Phase 2 Study of Intraoperative Radiation Therapy in Elderly Patients with Small Breast Cancer (TARGIT E) [PDF]

, 2017
Frederik Wenz
openalex   +1 more source

TREX1, a predator for treating MSI‐H tumors?

Molecular Oncology, EarlyView.
Immunotherapy benefits many patients; yet, some with MSI‐H tumors remain unresponsive despite their high immunogenicity. Xu et al. reveal that TREX1 enables immune evasion by degrading cytosolic DNA and suppressing cGAS–STING–IFN‐I signaling. TREX1 loss restores DNA sensing, increases CD8+ T and NK cell infiltration, and boosts antitumor immunity ...
Elena Benidovskaya, Joséphine Deneft, Marc Van den Eynde   +2 more
wiley   +1 more source

The Vascular Density/Angiogenesis Marker CD31/PECAM1 does not Correlate with Overall Survival in Neuroendocrine Tumors. [PDF]

J Gastrointest Cancer
Skill NJ, Avanzino K, Bren-Mattison Y, Boudreaux JP, Thiagarajan R, Maluccio M.   +5 more
europepmc   +1 more source

Increased Fiber Intake Results in Better Overall Survival and Lower GI-aGVHD in Allo-HCT Recipients and Pre-Clinical Gvhd Models [PDF]

Jenny Paredes, Teng Fei, Anqi Dai, Rúben Ramos, Peter Adintori, Anastasia I. Kousa, Chi L. Nguyen, Kristen Victor, Romina Ghale, Charlotte Pohl, Harold K. Elias, Oriana Miltiadous, Sébastien Monette, Ana Gradíssimo, Justin R. Cross, Jonathan U. Peled, Marina Burgos da Silva, Marcel R.M. van den Brink   +17 more
openalex   +1 more source

LINC01116, a hypoxia‐lncRNA marker of pathological lymphangiogenesis and poor prognosis in lung adenocarcinoma

Molecular Oncology, EarlyView.
The LINC01116 long noncoding RNA is induced by hypoxia and associated with poor prognosis and high recurrence rates in two cohorts of lung adenocarcinoma patients. Here, we demonstrate that besides its expression in cancer cells, LINC01116 is markedly expressed in lymphatic endothelial cells of the tumor stroma in which it participates in hypoxia ...
Marine Gautier‐Isola, Rafael Lopes Goncalves, Marin Truchi, Caroline Lacoux, Célia Scribe, Hugo Cadis, Laetitia Guardini, Sophie Bekisz, Marius Ilié, Paul Hofman, Georges Vassaux, Bernard Mari, Roger Rezzonico   +12 more
wiley   +1 more source

Impact of MGMT methylation on overall survival in solid tumors: A systematic review and meta-analysis. [PDF]

Exp Ther Med
Alzibdeh A, Khanfar A, Al-Hussaini M, Abuhijlih R, Mohamad I, Abdel-Razeq H, Abuhijla F.   +6 more
europepmc   +1 more source

Overall survival from breast cancer in women pregnant or lactating at or after diagnosis [PDF]

, 1996
Anne Lethaby, Michele A. O'Neill, Barbara H. Mason, I. M. Holdaway, Vernon Harvey   +4 more
openalex   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source